Last Updated: November 16, 2026

Qol Medical, Llc Company Profile

« Back to Dashboard


Biologic Drugs for Qol Medical, Llc

Applicant Tradename Biologic Ingredient Dosage Form BLA Patent No. Estimated Patent Expiration Source
Qol Medical, Llc SUCRAID sacrosidase Solution For Oral 020772 10,016,338 2036-12-20 Patent claims search
Qol Medical, Llc SUCRAID sacrosidase Solution For Oral 020772 10,577,154 2038-12-19 Patent claims search
Qol Medical, Llc SUCRAID sacrosidase Solution For Oral 020772 10,588,947 2037-12-15 Patent claims search
Qol Medical, Llc SUCRAID sacrosidase Solution For Oral 020772 10,912,714 2038-07-09 Patent claims search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Patent No. >Estimated Patent Expiration >Source

QOL Medical, LLC Competitive Landscape Analysis: Market Position, Patents, Exclusivity, and Strategic Outlook

Last updated: September 27, 2026

QOL Medical, LLC occupies a specialized position in the rare-disease pharmaceutical market through Sucraid (sacrosidase), an oral enzyme replacement approved for congenital sucrase-isomaltase deficiency, or CSID. The company has a narrow commercial portfolio, but Sucraid benefits from orphan-disease positioning, limited direct competition, physician familiarity, and a patient-support infrastructure built around a difficult-to-diagnose disorder.

The core strategic risk is patent and exclusivity erosion. Sucraid’s orphan exclusivity expired years ago, and no material active Orange Book patent barrier is publicly associated with the product. QOL’s practical defenses are therefore market-specific rather than patent-led: diagnostic expertise, patient access programs, clinical education, manufacturing know-how, product handling requirements, and relationships with specialty prescribers.

What products does QOL Medical, LLC commercialize?

QOL Medical is primarily associated with Sucraid, an oral solution containing sacrosidase, an enzyme that replaces deficient sucrase activity in patients with CSID.

Product Active ingredient FDA status Indication Commercial position
Sucraid Oral Solution Sacrosidase FDA-approved NDA 020772 Treatment of genetically determined sucrase deficiency in CSID Core and principal marketed asset

Sucraid is supplied as an oral liquid and is administered with meals or snacks. Its use depends on consistent dosing, refrigeration, product handling, and patient education. The product is not a conventional mass-market gastrointestinal medicine. Its commercial value comes from serving a small, identifiable patient population with limited approved treatment alternatives.

The FDA label describes Sucraid as an enzyme replacement therapy for sucrase deficiency associated with CSID. It does not replace all disaccharidase activity, so dietary management and clinical monitoring remain relevant to treatment decisions.[1]

How strong is QOL Medical’s market position in CSID treatment?

QOL has a strong position within the approved CSID treatment segment but a limited position in the broader gastrointestinal market.

Sources of market strength

QOL’s position rests on five factors:

  1. Sucraid has first-mover status as the principal FDA-approved pharmacologic treatment specifically directed at sucrase deficiency.
  2. CSID is a rare disease with substantial diagnostic complexity and symptom overlap with irritable bowel syndrome, lactose intolerance, inflammatory bowel disease, and other gastrointestinal disorders.
  3. Treatment requires specialist awareness, which raises the value of physician education and patient-identification programs.
  4. Patients and caregivers may face difficulty obtaining an accurate diagnosis, creating an advantage for companies with disease-specific support capabilities.
  5. Sucraid’s orphan-disease profile reduces the number of commercially interested competitors relative to larger gastrointestinal categories.

The market is not protected by a large number of competing branded products. Instead, Sucraid competes with dietary restriction, empiric treatment of gastrointestinal symptoms, diagnostic delay, and non-approved enzyme products.

Key commercial constraints

The same factors that create market protection limit growth:

  • CSID is underdiagnosed.
  • Symptoms are nonspecific.
  • Oral enzyme replacement must be used consistently with food.
  • Treatment adoption depends on confirmation of the diagnosis.
  • Reimbursement can require documentation and prior authorization.
  • The addressable patient population is much smaller than the population with general digestive symptoms.
  • The absence of a broad pipeline may limit QOL’s ability to diversify revenue.

QOL’s market share within approved CSID therapy can be high without translating into large absolute pharmaceutical revenue.

What patents protect Sucraid and sacrosidase?

Publicly available FDA Orange Book records do not show a material active patent estate for Sucraid comparable to the patent portfolios supporting newer small-molecule or biologic products.[2]

The principal protection categories are:

Protection type Sucraid position Strategic effect
Orange Book-listed patents No material active listing publicly associated with Sucraid Limited formal patent barrier to an ANDA or other competing pathway
Orphan-drug exclusivity Expired No current seven-year orphan exclusivity block
Formulation patents No material active, publicly identified barrier Limited protection against formulation competition
Method-of-use patents No material active, publicly identified barrier Limited litigation leverage based on use claims
Manufacturing know-how Potentially relevant May increase development and scale-up difficulty
Trademark and branding Commercially relevant Supports product recognition and patient retention
Regulatory dossier and experience Relevant Can slow competitors without creating statutory market exclusivity

Sacrosidase products may require meaningful manufacturing controls because the active enzyme is a biological material produced through a defined production process. That can create technical and quality barriers. It does not create the same legal exclusivity as an active patent or unexpired orphan designation.

Older patents covering enzyme production, stabilization, purification, or related formulations may exist historically, but any such patents would need to be evaluated individually for claim scope and expiration. They should not be treated as current Sucraid exclusivity without a live claim covering the marketed product or its approved use.

When did Sucraid lose exclusivity?

Sucraid received FDA approval in 2001. The product’s orphan-drug exclusivity period expired after seven years, generally in 2008, assuming the exclusivity period began on the approval date and was not extended by a later qualifying regulatory event.[3]

Milestone Date or status
FDA approval 2001
Orphan exclusivity Expired approximately 2008
Current FDA approval Remains listed in Drugs@FDA
Current patent barrier No material active Orange Book barrier publicly identified
Market status Commercially available specialty rare-disease product

The expiration of orphan exclusivity did not automatically produce generic entry. A competitor would still need to establish regulatory comparability, manufacturing capability, product quality, labeling, supply reliability, and commercial access.

What is the Orange Book status of Sucraid?

Sucraid is associated with FDA-approved NDA 020772. Public Orange Book information should be used to determine the current reference-listed-drug status and any listed patents or exclusivity codes.[2]

The commercial implication is significant: Sucraid appears to have a regulatory reference product but not a current patent-based barrier that would support conventional patent litigation against every potential entrant.

An entrant could evaluate several routes:

  • An abbreviated new drug application, if the product and regulatory framework support the required equivalence showing.
  • A 505(b)(2) application relying in part on FDA’s findings for sacrosidase.
  • A full NDA or biologics-oriented pathway if the product’s classification, manufacturing process, or formulation creates additional requirements.

The appropriate route would depend on FDA classification, dosage-form comparability, analytical methods, clinical bridging requirements, and the extent to which the proposed product differs from Sucraid.

Have generic manufacturers filed Paragraph IV challenges against Sucraid?

No prominent public Paragraph IV challenge or major federal patent litigation campaign involving Sucraid is broadly identified in the principal public drug-patent databases through the available record.

That outcome is consistent with the apparent lack of a meaningful active Orange Book patent estate. A Paragraph IV certification is most commercially relevant when the reference product has listed patents that create litigation risk or a 30-month stay. If no qualifying patents are listed, a challenger may not have a conventional Paragraph IV dispute to initiate.

The absence of a public challenge does not mean that generic entry is commercially imminent. CSID’s limited market size, specialized manufacturing requirements, low prescriber volume, and reimbursement complexity may reduce the expected return on development.

What generic entry risks exist for Sucraid?

Generic entry risk is moderate from a legal perspective and lower from a commercial execution perspective.

Legal risk

The absence of a strong patent estate reduces the probability that QOL could block an entrant through patent litigation. A new applicant would not face the type of layered composition, formulation, method-of-use, and manufacturing patent portfolio common in high-value specialty pharmaceuticals.

Regulatory risk

Sacrosidase is an enzyme product, and regulatory equivalence may be more complex than for a conventional chemically synthesized tablet. Relevant issues may include:

  • Enzyme activity and potency.
  • Product purity and impurity profiles.
  • Stability over the labeled storage period.
  • Microbiological controls.
  • Container-closure compatibility.
  • Assay validation.
  • Batch-to-batch consistency.
  • Demonstration of comparable clinical performance.

These issues can increase the cost and duration of development even without patent protection.

Commercial risk

A generic or follow-on product would need to build relationships with gastroenterologists, pediatric specialists, dietitians, specialty pharmacies, and patient-support organizations. The entrant would also need payer coverage and reliable distribution.

For QOL, the more immediate risk may be price pressure or payer substitution rather than a rapid full-market conversion to a competing product.

Does Sucraid face biosimilar competition?

Sucraid is not exposed to conventional monoclonal-antibody biosimilar competition. It is an enzyme replacement product administered orally, not a typical injectable therapeutic protein such as insulin, adalimumab, or trastuzumab.

The more relevant question is whether a competing sacrosidase product would follow an ANDA, 505(b)(2), or another FDA pathway. The regulatory classification and product-specific requirements determine whether the competitor must demonstrate pharmaceutical equivalence, therapeutic equivalence, clinical bridging, or a more extensive comparability package.

A future competitor could still create biosimilar-like commercial pressure through a highly comparable enzyme product even if the formal FDA pathway is not the biosimilar pathway under the Public Health Service Act.

What formulations are protected by QOL Medical?

Sucraid’s principal formulation is an oral sacrosidase solution. Publicly available information does not identify a current, high-value formulation patent that would prevent a competitor from developing another oral sacrosidase product.

The formulation itself creates operational requirements:

  • Refrigerated storage.
  • Controlled dispensing.
  • Administration with meals or snacks.
  • Avoidance of mixing with hot liquids because heat may reduce enzyme activity.
  • Patient-specific dosing and titration instructions.

These requirements are commercially relevant but are not equivalent to enforceable patent protection. A competitor could seek to differentiate through longer stability, simplified dosing, alternative packaging, improved taste, or easier distribution.

What manufacturing and intellectual-property barriers affect competitors?

Manufacturing may provide QOL with more practical protection than patents.

Enzyme production

Sacrosidase is produced through a biological process. The manufacturer must control source materials, fermentation or production conditions, purification, activity, impurities, microbial quality, and stability. Small process changes can affect enzyme activity and product consistency.

Analytical methods

A competing applicant would need reliable assays to demonstrate enzyme activity and product quality. The analytical package may be more demanding than the testing used for a standard small-molecule oral solid.

Supply chain

A specialty enzyme product requires dependable cold-chain logistics and controlled inventory. Shortages or shipping excursions can disrupt patient therapy and damage prescriber confidence.

Clinical know-how

QOL’s experience with CSID diagnosis and patient management can improve uptake even without exclusive legal rights. Disease-specific education may be difficult for a new entrant to replicate quickly.

Which companies are challenging QOL Medical?

No major public company has established a widely recognized competing FDA-approved sacrosidase product for CSID.

The competitive field consists of:

Competitor category Examples of competitive pressure Threat level
Direct approved drug competitors No prominent competing FDA-approved sacrosidase product publicly established Low
Generic or follow-on sacrosidase developers Potential ANDA, 505(b)(2), or other pathway entrants Moderate over the long term
Dietary management Low-sucrose or individualized carbohydrate restriction High as a substitute
Non-approved enzyme products Digestive enzyme supplements and compounded approaches Low to moderate
Diagnostic alternatives Symptom management without CSID confirmation High for market expansion
Future CSID therapies New enzyme, microbiome, gene-based, or nutritional approaches Low currently, but strategically important

The largest competitive challenge is not a named branded rival. It is failure to identify patients who could receive therapy.

What is QOL Medical’s FDA and regulatory position?

QOL benefits from an approved product with an established label and long-term commercial history. Sucraid’s approval gives the company a regulatory foundation that new entrants would need to match.

The regulatory asset includes:

  • An approved indication for CSID.
  • A known dosing framework.
  • Established safety information.
  • Product-specific manufacturing experience.
  • Postmarketing history.
  • Physician and pharmacy familiarity.

The limits are equally important. The approval does not provide current orphan exclusivity, and FDA approval alone does not prevent another applicant from developing a competing sacrosidase product.

What patent litigation and settlement agreements affect Sucraid?

No major public patent litigation or settlement agreement involving Sucraid is broadly identified in the principal federal patent-litigation and FDA drug-patent records available for review.

This limits QOL’s litigation overhang compared with branded drugs that face multiple Paragraph IV cases. It also means that the company’s commercial strategy depends less on litigation settlements and more on maintaining product availability, reimbursement, diagnosis, and patient support.

How does QOL Medical compare with larger rare-disease companies?

Factor QOL Medical Large rare-disease company
Portfolio breadth Narrow, centered on Sucraid Multiple products and development programs
CSID expertise High Generally limited unless directly active in the field
Patent depth Limited publicly visible estate Often layered patent portfolios
Commercial reach Specialized Broad specialty and institutional infrastructure
Revenue diversification Low Higher
Operational concentration High dependence on core product Spread across assets
M&A appeal Disease-specific platform and commercial niche Usually assessed by broader pipeline and scale

QOL’s narrow focus can support efficient disease-area execution. It also creates concentration risk if Sucraid faces supply disruption, reimbursement pressure, regulatory scrutiny, or a successful follow-on entrant.

What licensing deals and strategic transactions involve QOL Medical?

QOL Medical’s public profile is associated primarily with the commercialization of Sucraid rather than a large disclosed licensing portfolio. No major publicly disclosed licensing transaction comparable to the large biotech-pharma alliances involving milestone payments, territorial rights, or co-development obligations is broadly associated with Sucraid.

The strategic value of any historical rights transaction should be analyzed through:

  • Scope of licensed rights.
  • Remaining term.
  • Territory.
  • Manufacturing obligations.
  • Royalty burden.
  • Change-of-control provisions.
  • Rights to improvements and follow-on formulations.

Without a complete private-company filing and contract record, QOL’s royalty economics and acquisition liabilities cannot be quantified.

What is QOL Medical’s revenue exposure to Sucraid?

QOL is a private company and does not provide the level of segment reporting available from public pharmaceutical companies. Public revenue, gross margin, net sales, and product-level profitability figures are not broadly disclosed.

The commercial exposure is nonetheless clear:

  • Sucraid is the company’s principal publicly visible asset.
  • Product concentration is high.
  • Revenue depends on patient identification and diagnosis.
  • Reimbursement and specialty-pharmacy access are important.
  • A competitor could affect price and volume even without obtaining immediate broad formulary adoption.

For investors, licensors, or acquirers, Sucraid should be modeled using patient counts, diagnosed-patient growth, treated-patient penetration, adherence, net price, payer mix, and channel deductions rather than general gastrointestinal market size.

What generic launch scenarios are most likely?

Scenario 1: No near-term entrant

This is the base commercial scenario if the market remains too small to justify development investment. QOL retains pricing and volume control, subject to payer and access pressure.

Scenario 2: Specialty follow-on entrant

A smaller biotechnology or specialty pharmaceutical company develops a comparable sacrosidase product and targets high-volume gastroenterology practices. The entrant competes on price, packaging, or payer access.

Scenario 3: 505(b)(2) or full NDA entrant

A company develops a modified oral enzyme product with a differentiated formulation or stability profile. This could avoid direct product duplication but still pressure Sucraid.

Scenario 4: Non-drug diagnostic and dietary substitution

Improved diagnosis may increase Sucraid use, while better dietary protocols or non-approved enzyme products may reduce conversion to prescription therapy.

The fastest realistic competitive threat is likely a focused specialty entrant with payer and pharmacy capabilities, not a large generic manufacturer pursuing a high-volume automatic-substitution model.

How strong is QOL Medical’s overall competitive position?

QOL has a strong niche position and a weak conventional exclusivity position.

Dimension Assessment
Product differentiation Strong within approved CSID therapy
Patent protection Limited
Regulatory position Established
Orphan exclusivity Expired
Direct competition Limited
Diagnosis dependence High
Manufacturing complexity Moderate to high
Portfolio diversification Low
Generic vulnerability Moderate
Near-term commercial defensibility Moderate to strong
Long-term legal defensibility Limited

QOL’s strongest assets are market knowledge, disease-specific commercial infrastructure, and Sucraid’s established regulatory history. Its weakest assets are patent duration, product concentration, and the absence of a broad disclosed pipeline.

Key Takeaways

  • QOL Medical’s commercial position is centered on Sucraid, the principal FDA-approved pharmacologic treatment for CSID.
  • Sucraid received FDA approval in 2001, and its seven-year orphan exclusivity period expired approximately in 2008.
  • No material active Orange Book patent barrier is publicly associated with Sucraid.
  • No prominent Paragraph IV challenge, major patent litigation, or public settlement campaign is broadly identified.
  • Biosimilar competition is not the primary risk; the relevant threat is a generic, 505(b)(2), or follow-on sacrosidase product.
  • Manufacturing controls, enzyme analytics, cold-chain logistics, and disease-specific support create practical barriers.
  • QOL’s market position is strong within a narrow disease segment but exposed to product concentration and payer pressure.
  • The principal growth opportunity is improved CSID diagnosis and treatment penetration.
  • The principal strategic risk is a specialty entrant that combines comparable enzyme performance with lower pricing or stronger payer access.
  • QOL’s value is more likely to derive from niche commercial execution and regulatory know-how than from a long-dated patent estate.

FAQs About QOL Medical and Sucraid

Is Sucraid still FDA approved?

Yes. Sucraid remains associated with FDA-approved NDA 020772 for treatment of sucrase deficiency in patients with CSID.[1]

Can another company make a generic version of Sucraid?

Potentially. A competitor would need to satisfy FDA requirements for the applicable regulatory pathway and demonstrate adequate product quality, enzyme activity, stability, and clinical or equivalence support.

Does Sucraid have orphan-drug exclusivity today?

No. The original seven-year orphan exclusivity period associated with the 2001 approval expired approximately in 2008.

Is sacrosidase a biologic drug?

Sacrosidase is an enzyme product produced through a biological manufacturing process. Its regulatory pathway depends on FDA product classification and the specific characteristics of the proposed competing product. It should not automatically be treated as a conventional biosimilar product.

What would make QOL Medical attractive to a strategic buyer?

The main acquisition attributes would be an established rare-disease product, specialized CSID commercial infrastructure, patient and physician relationships, manufacturing expertise, and the potential to expand diagnosis or add adjacent gastrointestinal products. The primary diligence risks would be product concentration, limited patent protection, supply continuity, reimbursement, and the absence of a disclosed diversified pipeline.

References

  1. U.S. Food and Drug Administration. (n.d.). Sucraid (sacrosidase) oral solution prescribing information. Drugs@FDA.

  2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

  3. U.S. Food and Drug Administration. (n.d.). Orphan drug designation and exclusivity database. FDA.

  4. QOL Medical, LLC. (n.d.). Sucraid: Information for patients and healthcare professionals. QOL Medical.

  5. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs database. FDA.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.